Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US STOCKS-Wall St ends near flat after recent gains; healthcare climbs

Mon, 13th May 2013 20:42

* Core U.S. retail sales rise 0.5 percent in April

* Yum Brands falls as monthly Chinese sales drop

* Indexes: Dow down 0.2 pct, S&P flat, Nasdaq up 0.1 pct

By Caroline Valetkevitch

NEW YORK, May 13 (Reuters) - U.S. stocks ended flat onMonday, pausing after hitting record highs last week, butstrength in healthcare issues helped to keep declines in check.

The S&P 500 healthcare sector climbed 0.7 percentand was the day's best performer.

Shares of Theravance jumped 17.9 percent to $41.20after Irish drugmaker Elan agreed to a $1billion deal to buy 21 percent of the royalties that Theravancereceives from GlaxoSmithKline for itsrespiratory drugs.

The day's flat activity follows a third straight week ofgains on the major indexes, with both the Dow and S&P 500setting record closing highs last week. The S&P 500 remains up14.5 percent for the year so far.

While some analysts argue the long-term trend is stillhigher, many see momentum waning in the near term in the absenceof positive catalysts. Volume has been lighter than average, andvolatility has been low in recent days.

"Intraday volatility has essentially been nonexistent. Ithink it means people are really sitting on the sidelines rightnow seeing which way it's going to go," said Uri Landesman,president of Platinum Partners in New York.

The CBOE Volatility index ended down 0.3 percent.

The Dow Jones industrial average was down 26.81points, or 0.18 percent, at 15,091.68. The Standard & Poor's 500Index was up 0.07 points at 1,633.77. The NasdaqComposite Index was up 2.21 points, or 0.06 percent, at3,438.79.

Among the day's decliners, Yum Brands Inc fell 2percent to $68.92. After the market closed on Friday, the fastfood chain operator posted a steep decline in Chinese Aprilsales.

Helping to limit the market's downside, retail sales rose0.1 percent in April, better than the 0.3 percent drop that hadbeen expected, and returning to growth following a decline inMarch. Excluding autos, gasoline and buildingmaterials, core sales rose 0.5 percent. Retail sales account forabout 30 percent of U.S. consumer spending.

Investors are at odds over whether positive economic datacan help the market rise further, or whether it will spell theend of the Federal Reserve's monetary stimulus, which couldderail the rally, said Joseph Tanious, global market strategistat J.P. Morgan Funds.

Other data showed business inventories were unchanged inMarch for a second straight month, versus expectations of 0.3percent rise, suggesting restocking could help second-quartereconomic growth.

Earnings have been mostly better than expected. With 90percent of the S&P 500 having reported, 67.2 percent ofcompanies have topped earnings expectations, according toThomson Reuters data, even with the average over the past fourquarters. Only 46.9 percent have beaten revenue expectations,below the 52 percent average over the past four quarters.

U.S.-listed shares of Perion Network surged 10.6percent to $13.94 after the Israeli consumer Internet companyposted first-quarter earnings.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.